1
|
Leane M, Pitt K, Reynolds G, Tantuccio A, Moreton C, Crean A, Kleinebudde P, Carlin B, Gamble J, Gamlen M, Stone E, Kuentz M, Gururajan B, Khimyak YZ, Van Snick B, Andersen S, Misic Z, Peter S, Sheehan S. Ten years of the manufacturing classification system: a review of literature applications and an extension of the framework to continuous manufacture. Pharm Dev Technol 2024; 29:395-414. [PMID: 38618690 DOI: 10.1080/10837450.2024.2342953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2024] [Accepted: 04/10/2024] [Indexed: 04/16/2024]
Abstract
The MCS initiative was first introduced in 2013. Since then, two MCS papers have been published: the first proposing a structured approach to consider the impact of drug substance physical properties on manufacturability and the second outlining real world examples of MCS principles. By 2023, both publications had been extensively cited by over 240 publications. This article firstly reviews this citing work and considers how the MCS concepts have been received and are being applied. Secondly, we will extend the MCS framework to continuous manufacture. The review structure follows the flow of drug product development focussing first on optimisation of API properties. The exploitation of links between API particle properties and manufacturability using large datasets seems particularly promising. Subsequently, applications of the MCS for formulation design include a detailed look at the impact of percolation threshold, the role of excipients and how other classification systems can be of assistance. The final review section focusses on manufacturing process development, covering the impact of strain rate sensitivity and modelling applications. The second part of the paper focuses on continuous processing proposing a parallel MCS framework alongside the existing batch manufacturing guidance. Specifically, we propose that continuous direct compression can accommodate a wider range of API properties compared to its batch equivalent.
Collapse
Affiliation(s)
- Michael Leane
- Drug Product Development, Bristol Myers Squibb, Moreton, UK
| | - Kendal Pitt
- Leicester School of Pharmacy, De Montfort University, Leicester, UK
| | - Gavin Reynolds
- Oral Product Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield, UK
| | - Anthony Tantuccio
- Technology Intensification, Hovione LLC, East Windsor, New Jersey, USA
| | | | - Abina Crean
- SSPC, the SFI Centre for Pharmaceutical Research, School of Pharmacy, University College Cork, Cork, Ireland
| | - Peter Kleinebudde
- Faculty of Mathematics and Natural Sciences, Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Brian Carlin
- Owner, Carlin Pharma Consulting, Lawrenceville, New Jersey, USA
| | - John Gamble
- Drug Product Development, Bristol Myers Squibb, Moreton, UK
| | - Michael Gamlen
- Chief Scientific Officer, Gamlen Tableting Ltd, Heanor, UK
| | - Elaine Stone
- Consultant, Stonepharma Ltd. ATIC, Loughborough, UK
| | - Martin Kuentz
- Institute for Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, School of Life Sciences FHNW, Muttenz, Switzerland
| | - Bindhu Gururajan
- Pharmaceutical Development, Novartis Pharma AG, Basel, Switzerland
| | - Yaroslav Z Khimyak
- School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, UK
| | - Bernd Van Snick
- Oral Solids Development, Drug Product Development, JnJ Innovative Medicine, Beerse, Belgium
| | - Sune Andersen
- Oral Solids Development, Drug Product Development, JnJ Innovative Medicine, Beerse, Belgium
| | - Zdravka Misic
- Innovation Research and Development, dsm-firmenich, Kaiseraugst, Switzerland
| | - Stefanie Peter
- Research and Development Division, F. Hoffmann-La Roche AG, Basel, Switzerland
| | - Stephen Sheehan
- External Development and Manufacturing, Alkermes Pharma Ireland Limited, Dublin 4, Ireland
| |
Collapse
|
2
|
Yi Zheng A, Teng Loh M, Wan Sia Heng P, Wah Chan L. Selection of lubricant type and concentration for orodispersible tablets. Int J Pharm 2024; 657:124190. [PMID: 38701910 DOI: 10.1016/j.ijpharm.2024.124190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 04/04/2024] [Accepted: 04/30/2024] [Indexed: 05/05/2024]
Abstract
Lubricants are essential for most tablet formulations as they assist powder flow, prevent adhesion to tableting tools and facilitate tablet ejection. Magnesium stearate (MgSt) is an effective lubricant but may compromise tablet strength and disintegratability. In the design of orodispersible tablets, tablet strength and disintegratability are critical attributes of the dosage form. Hence, this study aimed to conduct an in-depth comparative study of MgSt with alternative lubricants, namely sodium lauryl sulphate (SLS), stearic acid (SA) and hydrogenated castor oil (HCO), for their effects on the tableting process as well as tablet properties. Powder blends were prepared with lactose, sodium starch glycolate or crospovidone as the disintegrant, and a lubricant at different concentrations. Angle of repose was determined for the mixtures. Comparative evaluation was carried out based on the ejection force, tensile strength, liquid penetration and disintegratability of the tablets produced. As the lubricant concentration increased, powder flow and tablet ejection improved. The lubrication efficiency generally decreased as follows: MgSt > HCO > SA > SLS. Despite its superior lubrication efficacy, MgSt is the only lubricant of four evaluated that reduced tablet tensile strength. Tablet disintegration time was strongly determined by tensile strength and liquid penetration, which were in turn affected by the lubricant type and concentration. All the above factors should be taken into consideration when deciding the type and concentration of lubricant for an orodispersible tablet formulation.
Collapse
Affiliation(s)
- Audrey Yi Zheng
- GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore
| | - Mahn Teng Loh
- GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore
| | - Paul Wan Sia Heng
- GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore
| | - Lai Wah Chan
- GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore.
| |
Collapse
|
3
|
Mohylyuk V. Effect of roll compaction pressure on the properties of high drug-loaded piracetam granules and tablets. Drug Dev Ind Pharm 2022; 48:425-437. [PMID: 36082906 DOI: 10.1080/03639045.2022.2123499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVE The aim of this study was to use an alternative granulation technique, solventless roll compaction, and to investigate the effect of the roll compaction pressure on the properties of granules and high-drug-loaded (80%, w/w) immediate release piracetam tablets.Significance. Piracetam commonly manufactured as high drug-loaded tablets by wet granulation with an aqueous binder solution. Due to its high solubility in water, the wet granulation process is largely susceptible to processing methods and can induce the uncontrolled polymorphic transition of piracetam as well as convert it into mono- and di-hydrates. METHODS The blends, comprising of piracetam, Kollidon® 30, and Avicel® PH-101 were roll compacted at 4, 5 and 13 MPa hydraulic pressure and calibrated using an industrial roll compactor. The resultant granules milled and raw piracetam were investigated with DSC. The resultant granules mixed with Ac-Di-Sol®, Aerosil® 200 Pharma, and magnesium stearate to prepare tablets using an industrial tablet press at the same compression force and 25, 65, and 100 rpm. The obtained tablets were film coated with an aqueous dispersion of Opadry® II using a pilot-scale solid-wall pan coater. RESULTS Roll compaction pressure influenced the polymorphic composition of piracetam, the granule properties and tablet mixture in relation to morphology, particle size, flowability, bulk and tapped density, as well as tablet hardness, tablet friability, disintegration, and dissolution. CONCLUSION This study showed the roll compaction can be successfully used for the preparation of highly water-soluble, highly drug-loaded piracetam film-coated tablets avoiding wet granulation pitfalls.
Collapse
Affiliation(s)
- Valentyn Mohylyuk
- School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK, Tel;
| |
Collapse
|
4
|
Jaspers M, Roelofs TP, Janssen PH, Meier R, Dickhoff BH. A novel approach to minimize loss of compactibility in a dry granulation process using superdisintegrants. POWDER TECHNOL 2022. [DOI: 10.1016/j.powtec.2022.117773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
6
|
Berardi A, Bisharat L, Quodbach J, Abdel Rahim S, Perinelli DR, Cespi M. Advancing the understanding of the tablet disintegration phenomenon - An update on recent studies. Int J Pharm 2021; 598:120390. [PMID: 33607196 DOI: 10.1016/j.ijpharm.2021.120390] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 02/01/2021] [Accepted: 02/10/2021] [Indexed: 10/22/2022]
Abstract
Disintegration is the de-aggregation of particles within tablets upon exposure to aqueous fluids. Being an essential step in the bioavailability cascade, disintegration is a fundamental quality attribute of immediate release tablets. Although the disintegration phenomenon has been studied for over six decades, some gaps of knowledge and research questions still exist. Three reviews, published in 2015, 2016 and 2017, have discussed the literature relative to tablet disintegration and summarised the understanding of this topic. Yet, since then more studies have been published, adding to the established body of knowledge. This article guides a step forward towards the comprehension of disintegration by reviewing, concisely, the most recent scientific updates on this topic. Initially, we revisit the mechanisms of disintegration with relation to the three most used superdisintegrants, namely sodium starch glycolate, croscarmellose sodium and crospovidone. Then, the influence of formulation, storage, manufacturing and media conditions on disintegration is analysed. This is followed by an excursus on novel disintegrants. Finally, we highlight unanswered research questions and envision future research venues in the field.
Collapse
Affiliation(s)
- Alberto Berardi
- Department of Pharmaceutical Sciences and Pharmaceutics Faculty of Pharmacy, Applied Science Private University, Amman 11931, Jordan.
| | - Lorina Bisharat
- Department of Pharmaceutics and Pharmaceutical Technology, School of Pharmacy, The University of Jordan, Amman 11942, Jordan
| | - Julian Quodbach
- Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University Duesseldorf, Germany
| | - Safwan Abdel Rahim
- Department of Pharmaceutical Sciences and Pharmaceutics Faculty of Pharmacy, Applied Science Private University, Amman 11931, Jordan
| | - Diego R Perinelli
- School of Pharmacy, University of Camerino, 62032 Camerino, MC, Italy
| | - Marco Cespi
- School of Pharmacy, University of Camerino, 62032 Camerino, MC, Italy
| |
Collapse
|
7
|
An improved method for the simultaneous determination of water uptake and swelling of tablets. Int J Pharm 2021; 595:120229. [PMID: 33484927 DOI: 10.1016/j.ijpharm.2021.120229] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2020] [Revised: 12/26/2020] [Accepted: 12/29/2020] [Indexed: 11/23/2022]
Abstract
Water uptake and swelling of tablets are processes occurring during active pharmaceutical ingredient (API) release. Thereby, disintegration is promoted and the enhanced exposure of API surface area to the release medium facilitates API dissolution. An experimental set-up for the simultaneous and time-resolved determination of water uptake and swelling of tablets has been developed. Water uptake was determined with a balance and swelling was determined with a camera. To validate the gravimetrical analysis, real-time water uptake measurements with inert test specimens were performed. The standard deviation of these measurements was considered to depict precision. A complementary gravimetrical analysis was employed to determine accuracy. For both, precision and accuracy, a maximum deviation of 6% was found. An algorithm for the symmetry-based 3D volume reconstruction was applied to obtain volumes of the tablets from 2D images. X-ray micro computed tomography was used to validate the accuracy and the determined volumes were in good accordance within 6% deviation. A case study with binary formulations of a filler and disintegrants confirmed reproducibility and demonstrated the ability of the method to discriminate formulation characteristics, such as disintegrant type, composition and porosity for water uptake and swelling with the necessary temporal resolution.
Collapse
|